Search ARM

InnoSkel is a pioneering bioscience platform company developing transformative therapies for the unmet needs of individuals with rare bone disorders. Initially the Company is developing a gene therapy for a group of diseases known as type II collagenopathies, whilst also expanding the use of its technology and know-how to target and treat other rare bone conditions. The Company’s goal is to make a meaningful difference to the lives of underserved patient populations suffering from severe bone disorders. Innoskel’s main offices and laboratories are in Sophia-Antipolis Biotechnology Park, Nice, France.

Contact Innoskel
Visit Website